Meralgia paraesthetica: LFCN entrapment in general practice

Burning and numbness on the outer thigh is a presentation that general practitioners encounter regularly, yet it is frequently misattributed to hip pathology or lumbar disc disease. Meralgia paraesthetica (MP) — entrapment of the lateral femoral cutaneous nerve (LFCN) at the inguinal ligament — is a pure sensory neuropathy with a well-defined distribution, a straightforward clinical test, and identifiable reversible causes. Most cases resolve with simple modification of the cause.

The Bernhardt–Roth syndrome is the eponymous label. The condition is more common in women (roughly 3:1 female to male predominance in Australian clinical series) and peaks in the third to fifth decades.

A. Core clinical — the AU general practice framework

The anatomy of the lateral femoral cutaneous nerve

The LFCN arises from the L2 and L3 nerve roots, exits the psoas major, crosses the iliac fossa, and passes under or through the inguinal ligament approximately 1–2 cm medial to the anterior superior iliac spine (ASIS). It then enters the thigh in the subcutaneous tissue and divides into anterior and posterior branches that supply sensation to the anterolateral thigh — a palm-sized patch on the lateral and front of the upper leg.

It is a purely sensory nerve. This is the key diagnostic feature: if there is any motor weakness or reflex change, the diagnosis is not meralgia paraesthetica, and further imaging is required to exclude lumbar nerve root compression, femoral neuropathy, or lumbosacral plexopathy.

Who gets meralgia paraesthetica

The incidence is approximately 4 per 10,000 per year in the general population, substantially higher in specific groups:

• Obesity (BMI ≥30) — altered nerve geometry at the inguinal ligament.
• Pregnancy — particularly the third trimester; uterine enlargement and altered gait mechanics compress the nerve; approximately 90% resolve within three months post-partum.
• People with diabetes — metabolic neuropathy increases vulnerability.
• Occupational belt wearers — police, military, tradespeople with heavy tool belts.
• Post-surgical — after pelvic surgery, hip arthroplasty, spinal surgery, or prolonged lithotomy or prone positioning on the operating table.

Bilateral meralgia paraesthetica occurs in approximately 5% of cases and warrants additional investigation to exclude systemic causes (diabetes, metabolic syndrome) or bilateral iatrogenic injury.

History and key features

The symptom pattern is characteristic:

• Burning, tingling, pins-and-needles, numbness in a discrete palm-sized area on the lateral and anterolateral thigh — not the knee, not the groin, not the inner thigh.
• Allodynia — light touch (clothing rubbing) is exquisitely uncomfortable, sometimes more so than deeper pressure.
• Worse with prolonged standing or walking, better with sitting or hip flexion (which releases inguinal ligament tension).
• Worse with tight clothing — a key history point that often confirms the diagnosis.
• Motor strength is preserved throughout — the patient walks normally and has full hip, knee, and ankle strength.

Ask about: belt tightness, clothing type, body weight change, pregnancy, recent pelvic or hip or spine surgery, and duration (most acute presentations resolve; symptoms persisting beyond three months are less likely to resolve without intervention).

Drug and metabolic history: HbA1c (diabetes), TSH (hypothyroid neuropathy), B12 and folate, vitamin D.

Examination

Inspection: assess BMI, look for tight belt or clothing, surgical scars, abdominal protrusion.

Pelvic compression test: patient lies on their side. The examiner applies firm pressure along the inguinal ligament for 30–60 seconds. Reproduction of the anterolateral thigh symptoms is a positive result — this is the best single clinical test for meralgia paraesthetica, with approximately 95% sensitivity per eTG. Release of compression is typically followed by rapid improvement in symptoms.

Tinel sign: tapping the inguinal ligament just medial to the ASIS reproduces paresthesia in the thigh distribution — positive in approximately 30%.

Sensory mapping: document the area of reduced or altered sensation. Does it match the LFCN territory?

Motor and reflexes: quadriceps strength and patellar reflex must be normal. Any weakness or absent knee jerk should redirect to imaging to exclude L2–L3 radiculopathy or femoral neuropathy.

Hip and lumbar spine: assess hip range of motion, trochanteric tenderness (to distinguish greater trochanteric pain syndrome), and perform a femoral stretch test (hip extension in prone — reproduces lumbar L2–L3 root pain, not MP).

Abdominal exam: masses, hernia (both can compress the LFCN via mass effect).

Differential diagnosis

The differentials requiring active exclusion are:

• L2–L3 lumbar radiculopathy — pain extends to the knee; hip flexor or thigh adductor weakness may be present; positive femoral stretch test; MRI lumbar spine if suspected.
• Femoral neuropathy — quadriceps weakness; absent patellar reflex; numbness extends to the medial leg (saphenous branch).
• Diabetic amyotrophy / lumbosacral radiculoplexopathy — in older patients with diabetes; progressive asymmetric proximal leg weakness and pain, often rapid onset; EMG/NCS essential.
• Greater trochanteric pain syndrome (GTPS) — lateral hip pain with tenderness directly over the greater trochanter; no neurological symptoms.
• Retroperitoneal mass — bilateral or persistent symptoms without obvious cause; CT abdomen and pelvis to exclude retroperitoneal malignancy, lymphadenopathy, or aortic aneurysm.
• Multiple sclerosis — if other neurological features, upper motor neurone signs, or age/sex profile atypical; MRI brain.

Investigations — when to order them

Classic meralgia paraesthetica is a clinical diagnosis. Investigations are ordered selectively:

• Bloods: HbA1c, TSH, B12/folate, vitamin D — in anyone with neuropathic features or diabetes risk.
• Ultrasound LFCN: emerging technique to visualise nerve anatomy and guide injection (MBS 55812).
• MRI lumbar spine: if L2–L3 radiculopathy cannot be confidently excluded clinically (MBS 63179 selectively rebatable).
• CT abdomen + pelvis: if atypical, persistent beyond six months, or bilateral — to exclude retroperitoneal mass or vascular pathology.
• EMG/NCS: confirms LFCN abnormality and excludes radiculopathy or femoral nerve disease — ordered by neurologist or on specialist advice.

B. Evidence appraisal — treatment options

First-line: reversible cause modification

For most patients, this is the only treatment needed:

• Remove the tight belt or clothing — the single most effective and immediately reversible intervention.
• Weight loss if BMI ≥30 — mechanical decompression by reducing abdominal pannus and altering nerve geometry at the inguinal ligament.
• In pregnancy — reassurance that 90% resolve post-partum; maternity support garments that avoid pressure at the inguinal ligament; avoid prolonged standing.
• Occupational modification — ergonomic redesign of tool belts, utility harnesses, and seated workstations.
• Post-surgical — time and reassurance (most iatrogenic cases improve over six to twelve months as the nerve recovers).

Second-line: analgesia and neuropathic agents

Simple analgesia (paracetamol, short-course NSAIDs) is appropriate for acute pain. Topical NSAIDs and topical capsaicin or lignocaine 5% patch offer localised symptomatic relief without systemic effects.

Neuropathic agents from eTG and AMH:

• Gabapentin 300–900 mg three times daily — PBS Authority Required for neuropathic pain; SafeScript/RTPM monitored.
• Pregabalin 75–300 mg twice daily — PBS Authority Required for neuropathic pain; SafeScript/RTPM monitored.
• Amitriptyline 10–25 mg at night — PBS general schedule; useful when sleep disruption co-exists; check ECG in older patients.
• Duloxetine 30–60 mg daily — PBS general; useful if comorbid depression.

NPS MedicineWise recommends shared decision-making regarding the burden of neuropathic agents versus their modest benefit in a condition that often resolves spontaneously.

Third-line: LFCN nerve block

A diagnostic and therapeutic ultrasound-guided nerve block with local anaesthetic (lignocaine) plus corticosteroid at the inguinal ligament. Approximately 80% of patients report short-term benefit (weeks to months). Ultrasound guidance by a pain specialist, sports physician, or interventional radiologist improves accuracy and reduces risk. Repeat injections (up to two to three) are reasonable for recurrence. Australian Physiotherapy Association — structured exercise and postural physiotherapy are useful adjuncts to injection.

Evidence quality is moderate (observational series); no large RCT comparing injection versus conservative management. The diagnostic value — confirming the LFCN is the pain generator — is itself clinically useful.

Fourth-line: surgery for refractory cases

Surgical intervention is warranted only after genuine failure of conservative management over three to six months, with significant impact on function and quality of life.

• Neurolysis (releasing the nerve from the inguinal ligament) — approximately 80% improvement; preferred first surgical option as nerve function is preserved.
• Transection — results in permanent numbness in the LFCN territory; reserved for last resort when neurolysis has failed or the nerve is too damaged to release.
• Pulsed radiofrequency ablation — less invasive, emerging evidence, available at specialist pain centres.

C. Australian operations

Meralgia paraesthetica is managed in general practice, with referral to a pain specialist or sports physician for injection, and neurosurgeon or orthopaedic surgeon for surgery. The Australian Pain Society maintains a directory of pain specialists.

Chronic disease management: meralgia paraesthetica persisting beyond six months with functional impairment qualifies for a GPCCMP (MBS 965/967), with relevant allied health including physiotherapist (postural correction, movement analysis), exercise physiologist (weight management, functional rehabilitation), and psychologist (CBT for chronic pain).

Mental Health Care Plan: MBS 2715/2717 — chronic neuropathic pain with sleep disruption, anxiety, and avoidance behaviour is a valid trigger.

Telehealth: MBS 91890/91891 for review of established patients and medication titration.

Workers’ compensation: occupational meralgia paraesthetica (police, military, tradespeople) should be documented and referred through the appropriate state workers’ compensation pathway.

PBS: paracetamol and NSAIDs are OTC. Gabapentin, pregabalin, amitriptyline, and duloxetine are PBS-listed (with Authority requirements noted above). Topical lidocaine patch is generally private cost. Capsaicin patches are PBS general schedule for neuropathic pain indications.

D. Special populations

Pregnancy: Meralgia paraesthetica is common in the third trimester and typically resolves within three months post-partum. Reassurance is the priority. Avoid NSAIDs in the third trimester. Paracetamol is safe. For severe disabling symptoms in pregnancy, an ultrasound-guided LFCN block using a minimal effective local anaesthetic dose (no corticosteroid in first trimester) is the most appropriate intervention, performed by an experienced pain specialist.

Obesity and metabolic syndrome: Weight loss addresses the root mechanical cause and has the strongest clinical support, but is also the most challenging to sustain. Referral to a dietitian through the GPCCMP, combined with exercise physiology and, where appropriate, pharmacological weight management (AMH), addresses the root cause more durably than any neuropathic agent.

Diabetes: Diabetic amyotrophy can mimic meralgia paraesthetica but causes motor weakness and is a distinct emergency requiring urgent neurology referral and tight glycaemic control. Confirm normal motor power before accepting a diagnosis of MP in any patient with diabetes.

Post-surgical: Iatrogenic meralgia paraesthetica after hip arthroplasty or pelvic surgery is common and usually resolves over six to twelve months as neuropraxia heals. Reassurance and time, with neuropathic agents for symptom relief if needed, is the management approach. Persistent symptoms beyond twelve months may warrant EMG/NCS and specialist surgical review.

When to escalate

Refer routinely (within six weeks) to a pain specialist or sports physician for ultrasound-guided LFCN block if three months of conservative management has not produced adequate relief.

Refer semi-urgently (within two weeks) to neurology if: typical MP features are absent, motor weakness is present, symptoms are bilateral without clear cause, or there is suspicion of a retroperitoneal mass.

Refer urgently or to the emergency department if: acute onset of saddle anaesthesia (both inner thighs plus perineum), bowel or bladder dysfunction, acute leg weakness — these suggest a different, urgent diagnosis.

What this article is and is not

This is general health information drawn from the Therapeutic Guidelines (eTG), Australian Medicines Handbook (AMH), NPS MedicineWise, and the Australian Pain Society. It does not constitute personal medical advice. The treatment of meralgia paraesthetica — including decisions about neuropathic agents and nerve blocks — requires individual assessment by your treating GP and, where appropriate, specialist input from a pain physician or neurologist.

For consumer-friendly information: HealthDirect, Better Health Channel.

---

Sources cited

1. Therapeutic Guidelines (eTG) — peripheral nerve entrapment
2. Australian Medicines Handbook
3. NPS MedicineWise — neuropathic pain
4. Australian Pain Society
5. Australian Physiotherapy Association
6. SafeScript — real-time prescription monitoring Victoria
7. HealthDirect
8. Better Health Channel